Monthly Archives: October 2022

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments

See more here:
Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 19,400 shares of TCR2’s common stock to 1 new non-executive employees. The stock options were granted as an inducement material to the employees’ acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4).

Originally posted here:
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.

More:
Vaccitech to Present at Upcoming October Investor & Scientific Conferences

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership or sale of one or both of the Company’s commercial products SYMJEPI® and ZIMHI®, a merger, sale, or reverse merger of the Company, and/or seeking additional financing.

Read more from the original source:
Adamis Announces Review of Strategic Alternatives

FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference.

Originally posted here:
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

Montrouge, France, October 3, 2022

See more here:
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a ‘Study May Proceed’ letter from the U.S. Food and Drug Administration (FDA), 30 days after submitting its Investigational New Drug (IND) application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin’s lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.

See the rest here:
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B...

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Robert Booth, PhD, has been appointed to its Board of Directors, effective immediately.

Read more here:
Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board

Read more:
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

CEO of Curis brings extensive biopharmaceutical financial experience to the Board

Continued here:
Imunon Appoints James E. Dentzer to its Board of Directors